Last edition
News about "Marc Kikuchi"
Glenmark Pharmaceuticals Launches Olanzapine for Injection 10 mg/vial Single-Dose Vial in US
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection 10 mg/vial, a bioequivalent and therapeutically equivalent generic to Zyprexa IntraMuscular Injection.
Marc Kikuchi | 06/07/2026 | By Akanki
Glenmark USA Launches Methylene Blue Injection USP 50 mg/10 mL
Glenmark Pharmaceuticals has launched Methylene Blue Injection USP 50 mg/10 mL, a bioequivalent and therapeutically equivalent generic version of ProvayBlue.
Marc Kikuchi | 17/06/2026 | By News Bureau
Glenmark Launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA has launched Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), a bioequivalent and therapeutically equivalent generic version of Vimpat Injection.
Marc Kikuchi | 05/06/2026 | By News Bureau
Glenmark Pharmaceuticals Launches Vancomycin for Injection USP in US
Glenmark Pharmaceuticals launches Vancomycin Hydrochloride for Injection USP in the US market, expanding its injectable portfolio in a segment valued at nearly USD 37.9 million annually.
Marc Kikuchi | 18/05/2026 | By News Bureau
Glenmark Takes Charge of RYALTRIS Commercialisation in US
Glenmark will handle end-to-end commercialisation and distribution of RYALTRIS nasal spray in the US, strengthening its respiratory portfolio presence.
Marc Kikuchi | 06/04/2026 | By News Bureau | 297
Glenmark Pharma USA Launches Generic Milnacipran Tablets
Glenmark Pharmaceuticals USA has launched Milnacipran Hydrochloride tablets in multiple strengths as the authorised generic of Savella, expanding treatment access in the US market.
Marc Kikuchi | 20/03/2026 | By News Bureau | 119
Glenmark Pharma USA Introduces Potassium Phosphates Injection USP
Glenmark Pharmaceuticals USA is set to launch Potassium Phosphates Injection USP in March 2026.
Marc Kikuchi | 19/03/2026 | By News Bureau
Glenmark Launches Epinephrine Injection Multi-Dose Vial
Glenmark has introduced its Epinephrine Injection USP, 1?mg/mL, 30?mg/30?mL multiple-dose vial, which is bioequivalent and therapeutically equivalent to the reference drug by BPI Labs, LLC (NDA 205029), offering a reliable alternative for patients and healthcare providers.
Marc Kikuchi | 23/12/2025 | By News Bureau | 181
Glenmark Pharmaceuticals to Launch Micafungin for Injection in US in September 2025
Glenmark Pharmaceuticals Inc., USA has announced the September 2025 launch of Micafungin for Injection USP, 50 mg and 100 mg vials, the bioequivalent of Astellas Pharma’s Mycamine.
Marc Kikuchi | 19/08/2025 | By Mrinmoy Dey | 334
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy